It’s not uncommon for companies who launch commercial drug products in the pre-filled syringe format to do so after initially using other product formats such as vials for the development and clinical trial phases. Switch-overs need careful and strategic consideration because doing so requires investment in the new format but also offers critical patient benefits and improved stakeholder outcomes.
Download this whitepaper to learn:
Vincenza Pironti, PhD., Global SME, Sterile Drug Product
Madhu Raghunathan, Director, Product Management
Roman Hlodan, Staff Scientist, R&D